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Abstract
Background: Cartilage plays a fundamental role in the development of the human skeleton. Early
in embryogenesis, mesenchymal cells condense and differentiate into chondrocytes to shape the
early skeleton. Subsequently, the cartilage anlagen differentiate to form the growth plates, which
are responsible for linear bone growth, and the articular chondrocytes, which facilitate joint
function. However, despite the multiplicity of roles of cartilage during human fetal life, surprisingly
little is known about its transcriptome. To address this, a whole genome microarray expression
profile was generated using RNA isolated from 18–22 week human distal femur fetal cartilage and
compared with a database of control normal human tissues aggregated at UCLA, termed Celsius.
Results: 161 cartilage-selective genes were identified, defined as genes significantly expressed in
cartilage with low expression and little variation across a panel of 34 non-cartilage tissues. Among
these 161 genes were cartilage-specific genes such as cartilage collagen genes and 25 genes which
have been associated with skeletal phenotypes in humans and/or mice. Many of the other cartilage-
selective genes do not have established roles in cartilage or are novel, unannotated genes.
Quantitative RT-PCR confirmed the unique pattern of gene expression observed by microarray
analysis.
Conclusion: Defining the gene expression pattern for cartilage has identified new genes that may
contribute to human skeletogenesis as well as provided further candidate genes for skeletal
dysplasias. The data suggest that fetal cartilage is a complex and transcriptionally active tissue and
demonstrate that the set of genes selectively expressed in the tissue has been greatly
underestimated.
Published: 12 June 2007
BMC Genomics 2007, 8:165 doi:10.1186/1471-2164-8-165
Received: 16 February 2007
Accepted: 12 June 2007
This article is available from: http://www.biomedcentral.com/1471-2164/8/165
© 2007 Funari et al; licensee BioMed Central Ltd. 
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), 
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.BMC Genomics 2007, 8:165 http://www.biomedcentral.com/1471-2164/8/165
Page 2 of 13
(page number not for citation purposes)
Background
Skeletogenesis begins with condensation of mesenchymal
chondroprogenitor cells to form the cartilage anlagen that
pattern the early skeleton. Subsequently, for bones that
grow by endochondral ossification, the chondrocytes dif-
ferentiate further to establish the growth plates. At the
joint surfaces, development of articular cartilage facilitates
and maintains joint movement during fetal life. These
multi-step processes require the coordinated expression of
many genes, including genes encoding extracellular
matrix proteins and morphogens, as well as proliferative,
angiogenic, and apoptotic signals [1]. Most of our knowl-
edge of the function of the genes involved has been
derived from developmental studies in model systems
and cell lines [2] as well as from the identification of dis-
ease genes in skeletal disorders.
Whole genome analysis of chondrocyte gene expression
has the potential to reveal novel genes and gene expres-
sion programs which define the tissue. Although the com-
plete set of genes expressed in human cartilage has not yet
been described, analysis of human cartilage cDNA librar-
ies has provided an initial in vivo picture of the cartilage
transcriptome [3-6]. These investigations have also identi-
fied expression of both known and novel genes. Compar-
ative microarray studies in rat cartilage [7] and several
chondrocyte cell lines [8,9] have provided a larger set of
genes of potential importance in chondrocytes, including
genes specific to the stages of chondrocyte differentiation.
Wang et al. (2004) identified 92 genes with two-fold var-
iation in expression between hypertrophic and prolifera-
tive growth plate chondrocytes. In this in vivo study,
significant gene expression changes were principally asso-
ciated with cell cycle, transcription, extracellular matrix
structure, receptor and transporter functions. In microar-
ray studies of mouse micromass cultures [8], 212 genes
exhibited at least a ten-fold difference in gene expression
as the cultures differentiated. Thus global characterization
of gene expression is beginning to describe the identities
of key regulatory molecules and their targets in chondro-
cytes.
Disrupting genes involved in the organization and matu-
ration of the growth plate and/or the stability of articular
cartilage results in inherited skeletal disorders that range
from perinatal lethal phenotypes to mild disorders with
early-onset osteoarthropathy as their major feature
[10,11]. Of the approximately 370 clinically distinguisha-
ble skeletal dysplasias [12], mutations in 115 genes have
been associated with about 150 disorders. Many of these
disease genes are expressed in a cartilage-selective pattern,
and therefore identifying additional genes uniquely
expressed in cartilage should yield new skeletal dysplasia
candidate genes.
To identify a larger set of genes uniquely expressed in
chondrocytes, this study describes a genome-scale gene
expression profile for 18–22 week human fetal cartilage.
There were 161 genes which appeared to be selectively
expressed in fetal cartilage, comprising a variety of novel
genes that may contribute to skeletal development. The
data suggest a complex pattern of cartilage gene expres-
sion and indicate that the number of genes selectively
expressed in cartilage has been greatly underestimated.
Results
Identification of cartilage-selective genes
To define a set of genes preferentially or uniquely
expressed in normal human fetal cartilage, cartilage
probeset intensities were compared with probeset intensi-
ties across a variety of normal tissues. A two-step process
was employed for gene identification, consisting of a
training step and a validation step (see the additional data
file 1, for a flow chart of an overview of the analysis). The
tissue-selectivity of a representative sampling of the iden-
tified genes was confirmed by quantitative RT-PCR.
The training dataset consisted of five independent carti-
lage samples and 41 non-cartilage samples, all analyzed
using Affymetrix U133 2.0 Plus arrays. The average corre-
lation coefficient among the cartilage samples (R2) was
0.96. To identify unbiased relationships within the data,
and to test the robustness of the normalization and tissue-
specificity, an unsupervised approach [13], in which the
genes and tissues were grouped based only on expression
patterns, was employed. Probesets with the greatest varia-
tion across all tissues and whose expression in any two
arrays differed by at least two standard deviations from
their mean expression across the entire set of samples
were selected. This selection yielded 9483 probesets.
Two-way hierarchical clustering based on similarity of
expression of these 9483 probesets within the samples
was performed (Figure 2). Samples from the same tissues
clustered together, indicating that the normalization was
sufficiently robust to allow tissue-selective expression pat-
terns to be identified. Even with these relatively non-strin-
gent selection criteria, the results showed a surprisingly
large number of genes with a fetal cartilage-selective
expression pattern. At least 89 probesets representing 64
genes with coordinately higher expression in cartilage rel-
ative to non-cartilage tissues appeared to drive the cluster-
ing of the two groups (Figure 2B). These probesets formed
a gene expression node in the dendrogram which shared
an overall expression correlation of 0.99. The genes repre-
sented by these probesets included some well established
cartilage-selective genes, including aggrecan (AGC1), type
× collagen (COL10A1), and matrilin 3 (MATN3), among
others. Thus, a comparative approach with microarrays
can identify genes whose expression is cartilage-selective.BMC Genomics 2007, 8:165 http://www.biomedcentral.com/1471-2164/8/165
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To define a ranked list of genes significantly expressed in
cartilage, a supervised analysis [13], comparing cartilage
versus non-cartilage gene expression, was employed. This
consisted of a two-class analysis with a modified t-test
(SAM) (See additional data file 2, for the complete results
of this analysis). There were 2634 probesets representing
1720 genes with at least three-fold differential expression
when comparing cartilage and non-cartilage tissues, with
a false discovery rate of zero. Of these, 2446 of the 2634
probesets demonstrated higher expression in cartilage
with respect to non-cartilage tissues, while the remaining
188 probesets were expressed at significantly higher levels
in the other tissues. As observed for the hierarchical clus-
tering, probesets representing well-known cartilage mark-
ers, including COL2A1,  AGC1,  COMP,  COL9A3, and
MMP3  were among the top genes listed. In addition,
lubricin (PRG4), an articular cartilage-specific marker, was
also identified, confirming the ability to identify genes
specific to fetal articular cartilage. Indeed, among the top
35 probesets more highly expressed in cartilage, only four
probesets, representing unannotated genes, were derived
from genes not previously known to be expressed in carti-
lage.
In silico validation
Three array platforms were used to validate the 2446
probesets identified in the supervised analysis and gener-
ate a robust list of cartilage-selective genes (Table 1). A
majority of these probesets (2245 probesets (> 92%))
were identified in 124 U133A and 74 U133B arrays using
the Celsius database (see Materials and Methods), and
represented expression from 34 normal tissues. A small
proportion of the probesets (201/2446) are not found on
the Affymetrix™ Human Genome U133A/B Arrays, so
these probesets were identified in the analysis of 26 U133
Plus 2.0 arrays, representing eight non-cartilage tissues. A
summary of the validation and the tissue distribution are
available as additional files.
Of the three platforms, the U133A dataset was the most
robust with regard to the number of arrays, biological rep-
licates, diversity of tissues, probes identified, and gene
annotation. From this platform, 1363 of the 2446
probesets identified in the SAM analysis as expressed at a
higher level in cartilage were obtained. Two hundred sev-
enty-four of the 1363 probesets (274/1363), representing
237 genes, exhibited at least five-fold higher expression
when compared to non-cartilage tissues and were ranked
by cartilage-specificity using an analog of coefficient of
variation (CV) (see Methods). Of these, 56 probesets, rep-
resenting 49 genes, were identified with a CV < 50% in
non-cartilage samples, constituting the cartilage-selective
gene set from this platform (Table 1, left). Twenty of these
genes have mutations that have been associated with skel-
etal phenotypes in humans and/or mice, representing
44% of the probes selected from this platform.
Eight hundred eighty-two of the 2446 probesets were
identified from the U133B validation set. Two hundred
fourteen of these probesets, representing 158 genes, were
well measured in cartilage with at least five-fold higher
expression in cartilage relative to non-cartilage tissues. Of
these, 77 probesets had a CV less than 50% in non-carti-
lage samples, representing 71 cartilage-selective genes
(Table 1, center), including 3 genes also identified using
the U133A platform (COL11A1, EDIL3, and PDPN).
A subset of the cartilage-selective genes was represented
only on the Human Genome U133 Plus 2.0 arrays and
were selected from the analysis of 28 non-cartilage sam-
ples. In total 201/2446 probesets were not represented in
the U133A/B array set. Of these 201 probesets, 96
probesets, representing 85 genes, had a five-fold higher
expression in cartilage than non-cartilage samples. By
including the CV selection criterion, 52 probesets, repre-
senting 50 cartilage-selective genes were identified and
added to the complete tally (Table 1, right), including 6
genes also identified using the U133A and U133B arrays
(IRAK2, NRP2, WTAP, PITPNC1, AKR1C2, and PTK2).
In summary, 480 genes demonstrating enriched or spe-
cific expression in cartilage were selected from the com-
Human fetal cartilage section dissected for RNA expression  profiling Figure 1
Human fetal cartilage section dissected for RNA 
expression profiling. (A) Normal distal femur cartilage 
from an 18–22 week fetus. Brackets define the cartilage that 
was dissected and used for RNA profiling. (B) Toluidine blue 
stained longitudinal section of the distal head of the femur 
magnified 8.5 fold. The dissected portion included chondro-
cytes from the articular, reserve, proliferating, and hyper-
trophic zones.BMC Genomics 2007, 8:165 http://www.biomedcentral.com/1471-2164/8/165
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Unsupervised analysis of all tissues using U133 2.0 microarrays Figure 2
Unsupervised analysis of all tissues using U133 2.0 microarrays. (A) Two-way hierarchical clustering of 46 normal tis-
sues (including five fetal cartilage and 41 non-cartilage tissues) and 9483 probesets which vary more than two standard devia-
tions from the mean expression of the probeset. As detailed in the Methods, to generate a cartilage-centric figure, the median 
cartilage signals were normalized to zero prior to the clustering. This resulted in cartilage gene expression being displayed to 
the left and expression among the non-cartilage tissues to the right and produced deep branching among the cartilage samples. 
Mean-centered clustering reflected the high correlation among the cartilage samples (average regression correlation of 0.92) 
and did not qualitatively alter the correlations among the non-cartilage samples (data not shown). (B) Zoomed image of gene 
expression from 89 probesets representing 64 genes containing many known cartilage-specific genes which distinguish fetal car-
tilage expression.
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Table 1: Cartilage-selective genes validated in silico on U133A (left), U133B (center), and U133 Plus 2.0 (right) platforms.
U133A 
SYMBOL
Probe CV Class Mouse Human SAM Fold U133B 
SYMBOL
Probe CV Class Mouse Human SAM Fold U133 2.0 
SYMBOL
Probe CV Class SAM Fold
AGC1 207692_s_at 9.0 ST x 14 65.6 COL11A1 229271_x_at 11.0 ST x x 3 54.2 FLJ16008 1568868_at 6.4 44 8.2
AGC1 217161_x_at 9.2 ST x 31 15.5 230895_at 230895_at 11.3 4 67.0 UBE3C 1560739_a_at 8.5 EZ 305 5.1
MATN1 206905_s_at 9.6 ST 22 75.3 EDIL3 233668_at 11.8 SI 221 6.0 1563414_at 1563414_at 8.8 77 5.1
COL10A1 217428_s_at 9.9 ST x x 284 5.9 C10orf49 236800_at 15.5 13 76.0 IRAK2 1553740_a_at 11.0 SI 107 6.3
MATN3 206091_at 10.1 ST x 32 6.7 IRAK2 231779_at 15.6 SI 158 25.1 COL25A1 1555253_at 11.4 ST 516 5.1
MMP13 205959_at 10.2 ME x x 6 28.9 SLC4A5 234976_x_at 16.3 EZ 1036 6.4 KIAA0701 1554292_a_at 11.6 57 5.9
MATN4 207123_s_at 10.4 ST 59 7.8 LOC399959 239672_at 16.4 633 10.2 SULT1C2 1553321_a_at 11.7 ME 105 7.5
AGC1 205679_x_at 10.6 ST x 18 28.6 IBSP 236028_at 16.4 SI 628 19.0 ITGB1 1561042_at 11.7 SI 542 7.0
COL11A2 216993_s_at 11.5 ST x x 116 7.3 EDNRA 243555_at 22.0 SI x 213 5.6 RP4-756G23.1 1557123_a_at 13.1 214 6.2
NOS2A 210037_s_at 11.6 SI 20 18.7 HSUP1 229899_s_at 22.2 1994 5.1 NRP2 1555468_at 13.7 SI 45 10.2
LECT1 206309_at 13.3 SI x 34 52.3 COL9A2 232542_at 22.5 ST x 1929 5.0 MSI2 1552364_s_at 14.2 SI 178 5.2
HAS2 206432_at 14.2 ME 91 5.4 CMAH 229604_at 23.0 EZ 272 8.0 PTGFR 1555097_a_at 17.0 SI 470 8.0
WISP1 206796_at 15.6 SI 15 7.1 SNX5 223666_at 23.1 SI 108 5.3 BCL10 1557257_at 17.5 EZ 1014 6.1
HAPLN1 205523_at 18.5 ST x 8 18.8 EDG2 232716_at 23.2 SI x 712 5.4 WTAP 1560274_at 17.5 SI 228 6.3
COL9A1 222008_at 19.4 ST x x 19 185.1 TNFRSF18 224553_s_at 23.9 SI 124 9.4 RUNX1 1557527_at 17.8 SI 297 13.0
C1QTNF3 220988_s_at 20.3 291 5.4 USP12 236975_at 23.9 EZ 1776 6.3 LACTB 1552485_at 18.6 EZ 659 6.5
COL11A2 213870_at 20.5 ST x x 11 136.9 RP6-213H19.1 224407_s_at 25.3 SI 313 5.8 WWP2 1552737_s_at 21.1 EZ 144 10.9
COL10A1 205941_s_at 20.5 ST x x 684 38.5 BIC 229437_at 26.9 SI 571 5.5 PITPNC1 1568949_at 21.5 SI 258 5.5
NGFB 206814_at 21.0 SI 78 7.1 KIAA1718 225142_at 27.8 651 11.5 ARIH1 1558710_at 22.2 EZ 1264 5.2
PDPN 204879_at 21.5 ST x 103 8.8 RB1CC1 237626_at 27.9 SI 1489 5.5 ADAMTS9 1554697_at 22.7 ME 769 7.4
222348_at 222348_at 21.8 227 8.4 WTAP 244219_at 28.1 SI 371 6.1 SYNJ2 1555009_a_at 23.7 SI 277 5.9
SLC28A3 220475_at 21.9 SI 296 5.1 RHOQ 239258_at 28.2 SI 784 5.4 SRGAP1 1554473_at 23.8 SI 809 5.1
EIF2C2 213310_at 22.4 EZ 1071 9.1 RPS6KA3 241460_at 28.3 SI x x 529 9.1 MGC17337 1552277_a_at 24.2 690 6.0
SOX5 207336_at 23.5 SI x 1250 8.2 SEMA6D 233801_s_at 29.1 SI 245 5.3 1555841_at 1555841_at 24.5 1606 6.8
DSPG3 206439_at 24.0 ME 5 15.0 FN1 235629_at 29.6 ST 622 10.5 CD44 1565868_at 24.8 SI 1025 6.2
COL11A1 37892_at 25.7 ST x x 12 82.4 ULBP2 238542_at 29.7 SI 101 6.1 SLC41A2 1562208_a_at 24.9 ST 407 8.7
COL11A1 204320_at 26.0 ST x x 73 63.6 229221_at 229221_at 30.1 176 7.6 RHOF 1554539_a_at 26.7 SI 704 6.4
SOD2 215078_at 26.2 EZ 76 10.7 PTK2 241453_at 30.2 SI 355 7.7 ARF1 1565651_at 27.7 SI 768 5.6
HSPC159 219998_at 27.6 EZ 126 8.1 CHST11 226368_at 30.6 ME 310 5.3 1552288_at 1552288_at 28.0 127 17.1
BMP2 205289_at 29.3 SI 591 17.4 VASN 225867_at 31.9 SI 593 5.9 B3GNT5 1554835_a_at 29.5 ME 331 5.5
CSPG4 214297_at 29.5 ST 17 39.5 SCUBE3 230290_at 33.3 SI 123 6.4 B3GNT7 1555963_x_at 30.4 ME 339 18.3
CHST3 32094_at 30.0 EZ x 1560 6.3 LOC338758 238893_at 33.4 998 5.2 SETD5 1569106_s_at 31.2 839 6.0
RELB 205205_at 30.1 SI 390 7.7 LOXL4 227145_at 33.8 EZ 260 7.5 OSMR 1554008_at 31.9 SI 85 50.3
CYTL1 219837_s_at 30.7 SI 151 17.0 SLC25A37 242335_at 33.9 SI 765 12.3 ZFYVE16 1554638_at 32.2 722 5.2
FZD10 219764_at 30.8 SI 51 7.3 228910_at 228910_at 34.0 630 5.4 AKR1C2 1562102_at 32.8 EZ 559 5.7
BDKRB1 207510_at 31.6 SI 239 5.1 PITPNC1 239808_at 34.3 SI 1129 11.8 WTAP 1558783_at 33.2 SI 946 8.0
ITGA10 206766_at 32.6 SI x 41 29.4 FNDC3B 222693_at 34.3 SI 1394 10.2 LRRC8C 1558517_s_at 33.4 731 5.3
RNF24 210706_s_at 32.6 774 5.1 PDPN 226658_at 35.2 ST 125 15.7 1552289_a_at 1552289_a_at 34.4 164 28.5
NUPL1 204435_at 33.0 SI 1680 5.2 LOC201181 241383_at 35.2 173 14.5 SFXN3 1559993_at 35.7 SI 160 7.8
RNF24 204669_s_at 33.0 1349 6.0 FNDC3B 244022_at 37.0 SI 456 7.3 LRP11 1561180_at 37.8 SI 393 10.3B
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AKR1C2 217626_at 33.6 EZ 595 12.3 CHST11 226372_at 37.9 ME 554 5.9 B3GNT7 1555962_at 38.2 ME 396 12.5
LOC283824 213725_x_at 35.5 1433 6.5 225611_at 225611_at 38.2 1117 7.4 ZNF146 1569312_at 38.3 374 10.5
PDLIM4 214175_x_at 35.6 SI 212 5.6 NRP2 232701_at 38.6 SI 58 6.5 ZCCHC7 1556543_at 41.5 1906 6.2
FOSL1 204420_at 37.8 SI x 458 15.2 TNFRSF10D 227345_at 38.7 SI 363 6.5 ATF1 1565269_s_at 42.0 SI 533 6.7
HAPLN1 205524_s_at 38.4 ST x 16 137.6 FNDC3B 232472_at 39.4 SI 327 5.9 HIG2 1554452_a_at 43.0 EZ 119 44.6
MIA 206560_s_at 41.0 ST x 36 8.1 229242_at 229242_at 39.7 330 6.3 KLF7 1555420_a_at 43.3 SI 1056 5.7
MMP12 204580_at 41.3 ME 29 8.2 ANKRD28 229307_at 39.7 SI 820 7.6 BCL2L11 1558143_a_at 43.8 EZ 683 6.2
TNMD 220065_at 41.9 ST x 113 5.0 TRPS1 234351_x_at 39.7 SI x 841 5.6 TGIF 1566901_at 43.8 SI 380 6.1
RLF 204243_at 43.0 SI 478 7.8 GLIS3 230258_at 40.2 SI 872 5.4 MCOLN2 1555465_at 43.9 520 8.6
EDIL3 207379_at 44.2 SI 84 5.4 SCUBE3 228407_at 40.2 SI 515 5.9 ChGn 1569387_at 44.7 ME 843 5.4
THBS3 209561_at 45.0 SI x 716 7.2 SCYL1BP1 226337_at 40.5 1714 6.9 PTK2 1559529_at 45.1 SI 562 6.2
MMP3 205828_at 46.6 EZ x 1 73.5 YME1L1 232216_at 40.9 ME 2251 5.5 FAM62B 1555830_s_at 49.5 837 6.6
RELA 209878_s_at 47.1 SI 971 7.3 KIAA0999 242920_at 41.0 1731 8.4
LIF 205266_at 47.9 SI 120 15.7 236289_at 236289_at 41.2 445 5.4
BMP6 206176_at 48.3 SI x 60 38.9 GALNTL2 236361_at 42.1 ME 290 15.7
ETNK1 219017_at 49.0 EZ 1400 5.1 PET112L 228441_s_at 42.2 EZ 333 9.8
ZNF697 227080_at 42.2 1119 5.5
FNDC3B 222692_s_at 42.3 SI 747 9.4
GPC6 223730_at 42.4 SI 511 9.5
COL27A1 225292_at 42.7 ST 135 5.4
NRP2 229225_at 43.1 SI 96 9.8
UFM1 242669_at 44.1 EZ 624 6.6
ASAM 228082_at 44.3 SI 68 11.7
KCNT2 234103_at 44.4 EZ 299 5.3
ERO1L 222646_s_at 44.6 EZ 1358 6.8
MAST4 225613_at 44.6 SI 642 7.9
228314_at 228314_at 44.7 1501 6.5
C8orf72 232668_at 45.0 400 15.6
RPS6 238156_at 45.7 EZ 1922 5.1
SQSTM1 244804_at 46.6 EZ x 1440 5.6
230204_at 230204_at 46.8 26 78.1
TBX15 230438_at 46.9 SI 932 5.9
244533_at 244533_at 47.0 752 5.5
235821_at 235821_at 47.2 35 9.9
ZNF160 239954_at 47.5 1897 7.1
SERPINE2 236599_at 47.9 EZ 80 12.1
236685_at 236685_at 49.5 1555 5.5
Genes were ranked by selectivity (CV) and classified into four functional classes Structural Protein (ST), Enzyme (EZ), Signaling (SI), and Extracellular Matrix Enzyme (ME). Genes associated with skeletal 
phenotypes in mice and/or human or genes are denoted in Mouse and Human columns, respectively. SAM defines the rank order of each gene identified by two-class SAM analysis of cartilage versus non-
cartilage tissues. The average cartilage expression divided by the median of non-cartilage expression (Fold) is listed for each gene.
Table 1: Cartilage-selective genes validated in silico on U133A (left), U133B (center), and U133 Plus 2.0 (right) platforms. (Continued)BMC Genomics 2007, 8:165 http://www.biomedcentral.com/1471-2164/8/165
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Table 2: Non-redundant set of 161 cartilage-selective genes 
organized by chromosomal location.
Chromosomal Location Symbol
chr1p11.1 TBX15
chr1p12 ZNF697
chr1p13.1 NGFB
chr1p21 COL11A1
chr1p22 BCL10
chr1p22 MCOLN2
chr1p22.2 228314_at
chr1p22.2 LRRC8C
chr1p31.1 PTGFR
chr1p32 RLF
chr1p33-p32 COL9A2
chr1p35 MATN1
chr1p36.21 PDPN
chr1p36.3 TNFRSF18
chr1q21 ITGA10
chr1q21 THBS3
chr1q24.2 SCYL1BP1
chr1q31.3 KCNT2
chr1q41 244533_at
chr1q42 ARF1
chr1q42.13 222348_at
chr2p13 SLC4A5
chr2p14 HSPC159
chr2p21 RHOQ
chr2p24-p23 MATN3
chr2q11.1-q11.2 SULT1C2
chr2q13 236289_at
chr2q13 BCL2L11
chr2q14.3 FLJ16008
chr2q32 KLF7
chr2q33.3 NRP2
chr2q33-q35 SERPINE2
chr2q34 FN1
chr2q37.1 B3GNT7
chr3p14.3-p14.2 ADAMTS9
chr3p24.3 ANKRD28
chr3p24.3 GALNTL2
chr3p25.3 IRAK2
chr3p25.3 SETD5
chr3q26.31 FNDC3B
chr3q28 B3GNT5
chr4p16-p15 CYTL1
chr4q21-q25 IBSP
chr4q22.1-q23 229221_at
chr4q25 COL25A1
chr4q27-q28 PET112L
chr4q31.23 EDNRA
chr4q35.1 1563414_at
chr5p13.1 OSMR
chr5p13.3 C1QTNF3
chr5p15.2-q14.3 ZFYVE16
chr5q12.3 225611_at
chr5q12.3 MAST4
chr5q14 EDIL3
chr5q14.3 230204_at
chr5q14.3 230895_at
chr5q14.3 HAPLN1
chr5q31.1 PDLIM4
chr5q35 SQSTM1
chr6p21.3 COL11A2
chr6p21.3 SCUBE3
chr6p21.32 CMAH
chr6q24.2 236685_at
parison of cartilage and non-cartilage tissues with data
derived from the U133A (n = 237), U133B (n = 158) and
U133 Plus 2.0 (n = 85) platforms. Of these, a non-redun-
dant set of 161 genes (Table 2), including 11 uncharacter-
ized genes and 16 genes represented by unannotated
probesets, were classified as cartilage-selective. These data
greatly expand the number of genes known to be selec-
tively expressed in cartilage and emphasize the unique
pattern of gene expression that determines its properties.
qRT-PCR validation
Quantitative RT-PCR was used to independently assess
the tissue-selectivity of the genes identified in the micro-
array analysis. For each of the three microarray platforms,
the probesets with a CV less than 50% were divided into
10% intervals (0–10% CV, 10–20% etc.) (Table 1), and
one gene from the middle of each interval was selected for
analysis by qRT-PCR.
All of the thirteen of genes analyzed demonstrated higher
expression in cartilage than in the seven non-cartilage tis-
sues studied (Table 3). Also, with one exception (OSMR),
the selection threshold of at least five-fold higher expres-
sion in cartilage tissues as compared with the average
expression among all non-cartilage tissues imposed for
the microarray analysis, was observed. For most of the
genes studied by qRT-PCR, there was little expression in
the seven non-cartilage tissues (median Ct = 33.2), indi-
cating that including the coefficient of variation in the
ranking algorithm preferentially identifies genes selec-
tively expressed in cartilage. Also, there was an inverse cor-
relation between the gene rank and the standard deviation
in expression level among non-cartilage tissues, indicating
that genes with a higher rank were more selectively
expressed in cartilage. Finally, there was a trend of decreas-
ing cartilage selectivity moving from the U133A to U133B
to U133 2.0 qRT-PCR validations, likely reflecting the
decreasing robustness of comparison datasets in the
respective platforms. Overall the qRT-PCR experiments
replicated and validated findings derived from the com-
parative microarray data.
Discussion
Using genome-scale microarrays, gene expression in
human fetal cartilage was compared with a robust set of
other normal tissues. Hierarchical clustering showed
remarkable similarity among the 18–22 week fetal carti-
lage expression profiles and demonstrated that a subset of
the cartilage transcriptome is composed of a unique gene
set not generally expressed in the other tissues studied.
Using SAM, 2446 probesets measured preferential expres-
sion of 1712 genes with at least three-fold higher expres-
sion in cartilage as compared with other tissues. 1028
(42%) of these probesets matched genes identified in a
cartilage growth plate cDNA library [4] validating theirBMC Genomics 2007, 8:165 http://www.biomedcentral.com/1471-2164/8/165
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chr6p24-p23 BMP6
chr6q12-q14 COL9A1
chr6q21-q22 COL10A1
chr6q25 ULBP2
chr6q25.1 LRP11
chr6q25.3 SOD2
chr6q25.3 SYNJ2
chr6q25-q27 WTAP
chr7q32.1 HIG2
chr7q34 KIAA1718
chr7q36.3 FAM62B
chr7q36.3 UBE3C
chr8p21 TNFRSF10D
chr8p21.2 SLC25A37
chr8p21.3 ChGn
chr8p22-q21.13 RB1CC1
chr8q12.1 C8orf72
chr8q24 EIF2C2
chr8q24.12 HAS2
chr8q24.12 TRPS1
chr8q24.1-q24.3 WISP1
chr8q24.22 235821_at
chr8q24-qter PTK2
chr9p13.2 ZCCHC7
chr9p21 RPS6
chr9p24.2 GLIS3
chr9q22.2 SLC28A3
chr9q31.1 1555841_at
chr9q31.1 MGC17337
chr9q31.3 EDG2
chr9q32 229242_at
chr9q32 COL27A1
chr10p11.2 ITGB1
chr10p13 C10orf49
chr10p14 YME1L1
chr10p15-p14 AKR1C2
chr10q22.1 CHST3
chr10q24 LOXL4
chr10q24.31 SFXN3
chr11p11.2 228910_at
chr11p13 CD44
chr11q13 FOSL1
chr11q13 RELA
chr11q22.3 MMP12
chr11q22.3 MMP13
chr11q22.3 MMP3
chr11q23.3 KIAA0999
chr11q24.1 ASAM
chr11q24.1 LOC399959
chr12p12.1 ETNK1
chr12p12.1 SOX5
chr12q CHST11
chr12q13 ATF1
chr12q14.2 SRGAP1
chr12q21 DSPG3
chr12q21.33 LOC338758
chr12q23.1 KIAA0701
chr12q23.3 SLC41A2
chr12q24.31 RHOF
chr12q24.33 FZD10
chr13q12.13 NUPL1
chr13q12.13 USP12
chr13q13.3 UFM1
chr13q14-q21 LECT1
chr13q32 GPC6
chr14q22.1 ERO1L
chr14q32.1-q32.2 BDKRB1
Table 2: Non-redundant set of 161 cartilage-selective genes 
organized by chromosomal location. (Continued) expression in cartilage via an independent dataset. The
identification of genes known to have restricted patterns
of expression in cartilage confirmed the presence of RNA
derived from the reserve (GREM1), hypertrophic (BMP6,
COL10A1), and terminally differentiated (MMP13)
chondrocytes, in addition to genes expressed throughout
all zones of the growth plate. This analysis suggested that
there is differential transcriptional regulation of many
genes in fetal cartilage and that the data could be used to
identify genes selectively expressed in the tissue.
Tissue-selective genes have been previously defined as
genes with enriched expression in a particular tissue [14]
and characterized with algorithms dependent on the
degree of differential expression relative to other tissues,
including t-test [15], SAM [16], fold change [14,17,18],
and enrichment scores [14]. While these approaches suc-
cessfully identify tissue-selective genes, the reliance on
fold change reduces the significance of many selectively
expressed genes with low fold change. To compensate for
this and identify cartilage-selective genes expressed at
lower levels, the approach presented here placed
increased significance on the preferentially expressed
genes that showed the least variation of expression in
non-cartilage tissues. This was made possible by the use of
publicly-released reference gene expression data per-
formed on the same platform and led to the reliable iden-
tification of genes with lower fold changes, but high
cartilage selectivity. The impact of the use of coefficient of
variation on the ranked gene list is apparent in Tables 1
and 2. In the U133A dataset, nine of the top 25 genes were
ranked higher than 100 in significance in the SAM rank-
ing. The average fold change of the probes for these nine
genes was 10.7, while the average fold change of the
probes for the other 14 of the top 25 genes was 42.2. One
of these probes, COL10A1 was among the top four carti-
lage-selective genes using the CV algorithm but ranked at
284 by SAM (Table 1). In the U133B dataset, which con-
tains a higher percentage of unannotated genes, 4 of the
top 50 probes had a SAM ranking below 100, and the
average SAM ranking was 576. Overall, to identify only
the most cartilage-selective genes, a threshold of 50%
coefficient of variation was used across all three platforms,
yielding 161 cartilage-selective genes. A subset of 13 of the
161 cartilage-selective genes was studied by quantitative
RT-PCR in cartilage and eight non-cartilage tissues to
independently assess tissue selectivity. The data con-
firmed the cartilage-selectivity of genes with less than 50%
CV, validating the selection procedure and suggesting that
the gene expression patterns determined by microarray
analysis are representative.
The coefficient of variation selection approach could, in
theory, equally select for three different patterns of expres-
sion: cartilage-specific genes; genes with a consistent levelBMC Genomics 2007, 8:165 http://www.biomedcentral.com/1471-2164/8/165
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chr15q21.1 SEMA6D
chr15q22.1 LACTB
chr15q24 ARIH1
chr15q24.2 CSPG4
chr15q26.1 AGC1
chr16p13.12 LOC283824
chr16p13.3 VASN
chr16q22.1 WWP2
chr17q11.2-q12 NOS2A
chr17q21.2 LOC201181
chr17q22 MSI2
chr17q24.2 PITPNC1
chr18p11.3 TGIF
chr19p13.11 1552288_at
chr19p13.11 1552289_a_at
chr19q13.1 ZNF146
chr19q13.32 RELB
chr19q13.32-q13.33 MIA
chr19q13.41 ZNF160
chr20p11 SNX5
chr20p12 BMP2
chr20p13-p12.1 RNF24
chr20q13.13 HSUP1
chr20q13.1-q13.2 MATN4
chr21q21.3 BIC
chr21q22.3 RUNX1
chr22q12.2 LIF
chr22q13.2 RP4-756G23.1
chrXp22.2-p22.1 RPS6KA3
chrXq21.33-q23 TNMD
chrXq26.2 RP6-213H19.1
Table 2: Non-redundant set of 161 cartilage-selective genes 
organized by chromosomal location. (Continued)
of baseline expression in non-cartilage tissues; and genes
with significant but equal expression in all tissues (e.g.
housekeeping genes). In this data analysis, however, the
most highly ranked genes consistently demonstrated little
or no expression in non-cartilage tissues. The data thus
demonstrate that incorporating coefficient of variation
preferentially selected for genes not significantly
expressed in non-cartilage tissues, yielding genes likely to
have important and perhaps unique roles in cartilage.
Regardless of expression level, a cartilage-selective expres-
sion pattern suggests that the product of each identified
gene may have a functional role in the development of the
skeleton. Concordant with this hypothesis, mutations in
25 of the 161 selected genes have been associated with
skeletal phenotypes in humans and/or mice. Included
among them were the products of the well characterized
genes encoding aggrecan and the cartilage-specific colla-
gens, gene products known to have a prominent role in
skeletal development and endochondral ossification. By
this measure, the remaining genes may be candidate genes
for skeletal dysplasias in which the disease gene has yet to
be identified. As new skeletal dysplasia loci are defined,
coincidence between a locus and a cartilage-selective gene
may promote rapid identification of the disease gene.
Knockout of the orthologous genes in mice would also
facilitate exploring the role of each gene in skeletal devel-
opment.
Classification of the biological roles of the products of the
cartilage-selective gene set reveals genes with diverse func-
tions including structural proteins of the cartilage extracel-
lular matrix, enzymes that modify them, and 41 gene
products with unannotated function. There were 65 genes
that are components of signaling pathways, and only 43%
of these were identified by sequence analysis of a compa-
rable fetal cartilage cDNA library [4]. Among the genes
were elements of the nitric oxide, VEGF, TNF/RANK, and
gp130 pathways, all of which have known roles in the
growth plate [19-23]. Mutations in the genes encoding
some of the molecules in these pathways, including
RPS6SKA3, LIFR, TNFRSF11A and IKBKG, have been asso-
ciated with human skeletal dysplasias [12], again suggest-
ing that the remaining genes may also serve critical roles
in endochondral ossification.
Multiple genes encoding members of the LIF/gp130 sign-
aling pathway met the definition of cartilage-selective
genes. LIF is a cytokine that is expressed in terminally-dif-
ferentiated growth plate chondrocytes [24] and signals
through the gp130/LIFR complex. Homozygosity for loss
of function mutations in the LIF receptor produces the
recessively inherited skeletal dysplasia, Stuve-Wiedemann
syndrome [25]. In addition to their skeletal features, these
patients have cardiovascular, pulmonary, gastrointestinal,
neurologic and metabolic abnormalities, likely attributa-
ble to the role that LIFR plays in embryonic or fetal devel-
opment. Genes on the cartilage-selective gene list
upstream of the receptor include RELA and RELB, NF-KB
survival transcription factors that increase transcription of
LIF [26], as well as the LIF gene itself. Through the LIFR/
gp130 complex, LIF can regulate both the JAK/STAT and
ERK MAP kinase pathways. Pathway components down-
stream of the receptor include ATF1, part of the ATF1/
CREB transcription factor complex that participates in
ERK MAP kinase signaling [27,28]. The ATF1/CREB com-
plex is also regulated by phosphorylation by the product
of the RPS6SKA3 gene [29,30], another gene in the MAPK/
ERK pathway that is associated with a skeletal phenotype.
The gene encoding RPS, a phosphorylation target of
RPS6SKA3 [30], was also cartilage-selective, but the role of
this protein in growth plate differentiation has yet to be
determined. Finally, the gene encoding FOSL1, a FOS-like
transcription factor activated by the ERK/MAPK pathway
which binds cJUN to form a transcription complex
[31,32], was among the cartilage-selective genes identi-
fied. Thus comparative microarray analysis has identified
multiple components of a regulatory pathway that can be
explored to further evaluate their importance in growth
plate differentiation and endochondral ossification.BMC Genomics 2007, 8:165 http://www.biomedcentral.com/1471-2164/8/165
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While this study has provided a deep set of genes that
exhibit a cartilage-selective expression pattern, there are
some limitations to the analysis. First, the study focused
on total cartilage RNA, including all types of growth plate
chondrocytes, as well as articular cartilage. As a result, it
cannot be determined if the selected genes are expressed
in all types of chondrocytes or only a subset of cells. In
this context, nine of the cartilage selective genes have been
shown to be more highly expressed in hypertrophic cells
relative to proliferating chondrocytes in the rat and/or
mouse [7,8]. Second, the cartilage samples were derived
from a single anatomic site and a narrow window of fetal
development, so it is unclear to what extent the observed
gene expression pattern can be generalized. Third, neither
all possible non-cartilage tissues nor each type of cell
within each tissue were studied, so cartilage-selectivity
could be affected if additional fetal and/or adult tissues
that express the identified genes were found. This may be
particularly important for other connective tissues such as
bone, tendon and ligament which contain cells known to
express some of the cartilage-selective genes identified
here.
Not all genes selectively expressed in developing cartilage
will necessarily be identified using this approach. For
instance, the COL2A1 gene fell just below the rigorous
50% CV standard set to define cartilage-selectivity. The
underlying reasons for this are complex. Probe perform-
ance as well as the known expression of COL2A1 in fetal
liver and heart, are likely to have had an effect, as both fac-
tors could have contributed to the variation in expression
in non-cartilage tissues. In addition, the approach pre-
sented here treated the three expression platforms,
U133A, U133B and U133 2.0 equally from the viewpoint
of the threshold for cartilage-selectivity. Because the com-
parative dataset of normal tissues was both broader and
deeper for the 133A platform, additional genes from this
platform, albeit with greater than 50% CV, could be con-
sidered to be tissue-selective (e.g. COL2A1). Thus, a plat-
form independent threshold would likely yield additional
genes of interest within the U133A dataset. Finally, tissue-
specific genes were identified using only microarrays and
a single generalized algorithm. Additional genes selec-
tively expressed in cartilage could be identified by less
stringent criteria or other methods.
Conclusion
Genome-scale comparative expression analysis using
human fetal cartilage and a broad set of normal human
tissues has identified 161 cartilage-selective genes, includ-
ing 27 uncharacterized genes. The data identify novel gene
products that may provide essential roles in normal skel-
etogenesis and suggest new candidates for the over 100
inherited skeletal disorders in which the disease gene has
not been identified. The results demonstrate that fetal car-
tilage is a complex and transcriptionally active tissue, and
that the set of genes selectively expressed in cartilage has
been greatly underestimated.
Methods
A flow chart outlining methods and results as well as other
supplemental information is provided in additional data
file 1.
Cartilage specimen collection and processing
Seven independent 18–22 week normal human fetal car-
tilage samples were studied under an Institutional Review
Board approved protocol. Cartilage from the distal femur
was dissected to remove bone and any adherent non-car-
tilage tissue (Figure 1). RNA was isolated and purified as
previously described [4] and the quality and quantity of
RNA were confirmed using an Agilent 2100 bioanalyzer
and a Nanodrop ND-1000 spectrophotometer, respec-
tively. Probe labeling, microarray hybridization, washing
and scanning were carried out as detailed in Affymetrix
protocols [33]. Five samples were used to probe Affyme-
trix™ U133 Plus 2.0 microarrays; and two samples were
used to probe the Affymetrix™ Human Genome U133A/B
set. Annotations were from version 11/15/06. The data are
publicly available in the GEO database series
Table 3: Summary of qRT-PCR amplification of cartilage-
selective genes in fetal cartilage and seven non-cartilage tissues.
CV Ct
Interval Symbol Neg NC C Fold
U133A
0–10% AGC1 23 3 2 3 3 7 1
10–20% NOS2A1 33 4 2 3 1 1 5 8
20–30% DSPG3 63 5 2 5 6 6 1
30–40% BDKRB1 23 4 2 84 9
40–50% MMP3 33 3 2 0 4 9 8 8
U133B
10–20% C10orf49 7 35 23 Unique
20–30% KIAA1718 30 27 8
30–40% LOC20118 43 4 2 92 0
40–50% ASAM 31 26 29
U133 2.0
10–20% KIAA0701 30 27 5
20–30% MGC17337 30 27 5
30–40% OSMR 28 27 3
40–50% HIG2 30 25 21
Representative genes are listed from each validation platform in order 
of 10% CV interval. (Neg) Number of non-cartilage tissues in which 
amplification was not detected. Average Ct values for each gene were 
calculated for both cartilage (C) and non-cartilage (NC) tissues. 
Where no amplification was observed the maximum Ct value (i.e. 35) 
was used for calculations. Fold difference (Fold) is calculated from the 
difference in cartilage and non-cartilage Ct values.BMC Genomics 2007, 8:165 http://www.biomedcentral.com/1471-2164/8/165
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[GEO:GSE6565]. An additional sample was fixed in for-
malin, sectioned and stained with toluidine blue.
Non-cartilage microarray data
This project made use of the Celsius database [34,35],
which is a database of publicly available microarray data-
sets from Gene Expression Omnibus, Array Express, and
individual databases. Only CEL files are entered into the
database, permitting reprocessing using identical algo-
rithms to enable experimental comparisons. Only data
from Affymetrix™ Human Genome U133A/B and Plus 2.0
platforms that contained clear annotation that they were
derived from normal human tissues were selected for this
analysis.
Microarray analysis
Data normalization and transformation
Raw data were normalized using the RMA algorithm with
default parameters, available as part of the Bioconductor
R library [36,37]. In brief, each CEL file was processed sep-
arately with an invariant pool of 50 arrays from a match-
ing platform. Higher signal intensities observed in a
subset of U133A non-cartilage samples from one provider
[38] were additionally normalized by subtracting the
median from other non-cartilage samples. After normali-
zation, the training dataset was log2 transformed prior to
analysis.
Median derived analog of CV for cartilage-selectivity 
ranking
In highly expressed cartilage genes, the degree of cartilage
selectivity was defined as a median derived analog of CV
(average deviation/median) applied to expression of these
genes in non-cartilage tissues. The analog of CV was used
to allow for greater tolerance of gene expression in some
cartilage containing tissues without affecting the cartilage-
selective assessment. A CV of 50% was empirically deter-
mined as a mathematically acceptable threshold for carti-
lage selectivity for probes across all three validation
datasets (U133A, U133B, and U133 Plus 2.0).
Training
For the unsupervised analysis, probe intensities in all tis-
sues were subtracted by the median probe intensity in car-
tilage, so all expression was defined relative to cartilage
(i.e. the median of cartilage expression was set at zero) for
each selected probe. Probesets with the greatest variation
across all tissues and whose expression in at least two sam-
ples differed by two standard deviations from their mean
expression across the entire set of samples were selected.
Two-way hierarchical clustering was performed using
Pearson's correlation to group genes and arrays based on
the similarity of their expression patterns [39]. For the
supervised analysis, the significance analysis of microar-
rays (SAM) two class method [40] was applied. 100 hun-
dred permutations were used and at least three-fold
variation between cartilage and non-cartilage expression
was required.
Validation
The probeset expression profiles for the 2,446 probesets
identified in the training set (see Results) were acquired
from 224 arrays representing 34 different tissues on three
different platforms: Affymetrix U133A, U133B and U133
Plus 2.0. The data from the first platform, U133A, con-
sisted of 1363 probeset profiles from 124 arrays, repre-
senting two normal fetal cartilage and 122 normal non-
cartilage (32 tissues) samples (see additional data file 3,
for the tissue distribution of samples used in this analy-
sis). Arrays represented in this dataset were mostly from
two large normal tissue expression profiling projects [38].
The second dataset, U133B, consisted of 882 expression
profiles identified on 72 U133B microarrays from two
normal fetal cartilage and 74 normal non-cartilage sam-
ples. These samples were primarily from the UCLA nor-
mal tissue microarray project (Chen, Day and Nelson,
unpublished). The U133 2.0 dataset consisted of 201
expression profiles obtained from 26 Human Genome
U133 Plus 2.0 arrays representing expression from five
normal fetal cartilage and 21 non-cartilage (eight different
tissue types) samples. The five cartilage arrays for the
U133 2.0 platform were technical replicates of the arrays
used in the training dataset. The non-cartilage arrays were
a subset of the training dataset set aside for this validation
only. From the 2446 probesets selected, probesets that
exhibited at least a five-fold difference between the aver-
age cartilage intensity and the median signal intensity of
all non-cartilage tissues, were selected. Cartilage-specifi-
city was then determined using a median-derived analog
of coefficient of variation (CV) as described above.
Probesets with less than 50% CV were defined as reflect-
ing cartilage-selective expression.
qRT-PCR
One microgram of RNA from seven tissues (brain, pros-
tate, kidney, liver, heart, thyroid, and testis) in the FirstCh-
oice®  Human Total RNA survey panel (Ambion) was
reverse transcribed using a high-capacity cDNA archive kit
(ABI) and random primers. For cartilage, RNA from three
independent cartilage samples was pooled and reverse
transcribed. Amplification reactions were performed in
triplicate using 100 ng of each cDNA. Thirty-five cycles of
amplification were carried out in an ABI 7300 using the
validated QuantiTect Gene Expression Assays and SYBR
Green PCR kit (Qiagen). To assess specificity, amplifica-
tion products were subjected to melting curve analysis
and gel electrophoresis. The 2- [delta] [delta]Ct method
was employed to calculate relative amplification. This was
performed using an average of endogenous references
(18S,  GAPDH, and HPRT1) to improve normalizationBMC Genomics 2007, 8:165 http://www.biomedcentral.com/1471-2164/8/165
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across the panel of tissues used [41]. For genes where no
amplification was detected in a tissue, a Ct value of 35 was
assigned, reflecting the maximum number of cycles car-
ried out.
Abbreviations
CV: coefficient of variation; SAM: significance analysis of
microarrays
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